| *P. falciparum* | *P. vivax* |
---|

| | Base model | _{mol}FOB adjusted | | Base model | _{mol}FOB adjusted |
---|

| IR | IRR (CI_{95}) | p | IRR (CI_{95}) | p | IR | IRR (CI_{95}) | p | IRR (CI_{95}) | p |
---|

Areas of residence |

Ilahita 1–4, 6, 7 | 0.05 | Reference group | 0.06 | Reference group |

Balanga & Balif | 0.03 | 0.63 (0.13–3.14) | 0.575 | 0.56 (0.11–2.81) | 0.485 | 0.06 | 1.15 (0.32–4.06) | 0.833 | 1.08 (0.30–3.91) | 0.909 |

Kamanokor & Ilahita 5 | 0.25 | 4.30 (1.59–11.6) | 0.004 | 3.96 (1.46–10.8) | 0.007 | 0.52 | 8.01 (3.23–19.9) | < 0.001 | 3.86 (1.44–10.3) | 0.007 |

Sunuhu 1&2 | 0.50 | 8.15 (3.40–19.6) | < 0.001 | 6.48 (2.65–15.8) | < 0.001 | 0.33 | 3.71 (1.53–8.99) | 0.004 | 2.00 (0.77–5.17) | 0.152 |

| | *p* < 0.0001^{a} | | *p* < 0.0001^{a} | | | *p* < 0.0001^{a} | | *p* < 0.0234^{a} | |

Age | | 1.38 (1.10–1.73) | 0.006 | 1.30 (1.03–1.64) | 0.026 | | | | | |

Haemoglobin | | 0.52 (0.35–0.77) | 0.001 | 0.61 (0.40–0.92) | 0.017 | | 0.31 (0.19–0.48) | < 0.001 | 0.38 (0.24–0.59) | < 0.001 |

FOB^{b} | | | | 1.10 (1.02–1.18) | 0.008 | | | | 1.17 (1.09–1.25) | < 0.001 |

- Multivariate negative binomial regression model-based estimates predicting risk of clinical
*P. falciparum* and *P. vivax*. Backward selection approach was used to derive significant associations. Base models included all variables except _{mol}FOB. Incidence is based on aggregated clinical data for entire 10-month study period thus precluding analysis of recent antimalarial treatment as a covariate. Bednet use was not analysed due to non-converge of data when included into models. ^{a}Overall significance level for the variable estimated using wald chi-square test; _{mol}FOB: molecular force of blood-stage infections; ^{b}_{mol}FOB was included as a rate; IR: Incidence rate; IRR: Incidence rate ratio. *CI*_{95} 95% confidence interval; *p p* value